Free Trial
NASDAQ:BIVI

BioVie (BIVI) Stock Price, News & Analysis

BioVie logo
$0.95 +0.11 (+13.37%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$0.86 -0.10 (-10.11%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About BioVie Stock (NASDAQ:BIVI)

Key Stats

Today's Range
$0.80
$1.00
50-Day Range
$0.84
$2.01
52-Week Range
$0.80
$7.50
Volume
274,290 shs
Average Volume
1.74 million shs
Market Capitalization
$17.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Strong Buy

Company Overview

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Remove Ads

BioVie Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

BIVI MarketRank™: 

BioVie scored higher than 52% of companies evaluated by MarketBeat, and ranked 519th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioVie has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioVie has only been the subject of 1 research reports in the past 90 days.

  • Read more about BioVie's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioVie is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioVie is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioVie has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about BioVie's valuation and earnings.
  • Percentage of Shares Shorted

    7.06% of the float of BioVie has been sold short.
  • Short Interest Ratio / Days to Cover

    BioVie has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioVie has recently decreased by 23.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    BioVie does not currently pay a dividend.

  • Dividend Growth

    BioVie does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.06% of the float of BioVie has been sold short.
  • Short Interest Ratio / Days to Cover

    BioVie has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioVie has recently decreased by 23.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    BioVie has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for BioVie this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for BIVI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added BioVie to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioVie insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of BioVie is held by insiders.

  • Percentage Held by Institutions

    Only 4.59% of the stock of BioVie is held by institutions.

  • Read more about BioVie's insider trading history.
Receive BIVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter.

BIVI Stock News Headlines

BioVie announces board member resignation
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
BioVie initiated with a Buy at Brookline
BioVie partners with New to The Street for media campaign
See More Headlines

BIVI Stock Analysis - Frequently Asked Questions

BioVie's stock was trading at $2.00 at the beginning of the year. Since then, BIVI shares have decreased by 52.4% and is now trading at $0.9523.
View the best growth stocks for 2025 here
.

BioVie Inc. (NASDAQ:BIVI) released its quarterly earnings data on Tuesday, February, 11th. The company reported ($0.46) earnings per share (EPS) for the quarter.

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioVie investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Hon Hai Precision Industry (HNHPF), Main Street Capital (MAIN), Ares Capital (ARCC) and PIMCO Dynamic Income Fund (PDI).

Company Calendar

Last Earnings
2/11/2025
Today
4/03/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BIVI
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+215.0%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.54 per share
Price / Book
0.37

Miscellaneous

Free Float
17,714,000
Market Cap
$17.57 million
Optionable
No Data
Beta
0.51
10 Stocks Set to Soar in Spring 2025 Cover

Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.

Get This Free Report

This page (NASDAQ:BIVI) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners